Personalised Medicine

AFor much of medical history, treatments have been designed for the average patient, operating on the assumption that a single drug or therapy will produce similar outcomes across diverse populations. This one-size-fits-all approach, while practical in many respects, has frequently resulted in ineffective treatments and avoidable side effects for a significant proportion of individuals. In recent decades, however, a transformative shift has begun to take shape. Personalised medicine — sometimes referred to as precision medicine — represents a fundamental rethinking of how diseases are diagnosed and treated, placing the individual patient's unique biological profile at the centre of clinical decision-making.

BAt the core of personalised medicine lies the science of genomics, which involves the comprehensive analysis of an individual's genetic material. Advances in DNA sequencing technology have made it possible to identify specific genetic variants that may predispose a person to certain diseases or influence how they are likely to respond to particular medications. Consequently, oncologists have already begun tailoring cancer treatments based on the molecular characteristics of a patient's tumour rather than simply its anatomical location. Given that two patients with breast cancer may carry entirely different genetic mutations, the same chemotherapy regimen could prove highly effective for one and largely ineffective for the other. This insight has driven considerable investment in targeted therapies and companion diagnostic tools worldwide.

CBeyond cancer treatment, personalised medicine appears to hold considerable promise in the management of chronic conditions such as cardiovascular disease, diabetes, and mental health disorders. Pharmacogenomics — the study of how genes affect a person's response to drugs — could allow physicians to prescribe the most appropriate medication at the optimal dose from the outset, thereby reducing the costly and often distressing process of trial and error. Furthermore, biomarker testing has already been integrated into routine clinical practice in several high-income countries, enabling earlier and more accurate diagnoses. In the context of mental health, genetic profiling may eventually guide the selection of antidepressants, a field in which treatment response has historically been difficult to predict.

DNevertheless, it would be premature to suggest that personalised medicine is without significant obstacles. The vast quantities of genomic and clinical data required to make reliable predictions raise serious concerns regarding data privacy and security. Moreover, the high cost of genetic testing and targeted therapies has meant that access remains largely confined to wealthier nations, potentially widening existing global health inequalities. Critics have also pointed out that the relationship between genes and disease is rarely straightforward; environmental, lifestyle, and socioeconomic factors interact with genetic predispositions in complex ways that current models have not yet fully captured. In contrast to the optimism expressed in much of the scientific literature, some researchers argue that the clinical benefits of personalised approaches have so far been demonstrated in only a narrow range of conditions.

EDespite these challenges, the trajectory of personalised medicine suggests that its influence on healthcare will continue to grow. International collaborations such as large-scale biobank projects have begun generating the datasets necessary to validate predictive models across ethnically diverse populations, a development that could help address concerns about representativeness in genomic research. If regulatory frameworks are updated to keep pace with scientific advances, and if healthcare systems invest in both infrastructure and workforce training, personalised medicine may ultimately deliver on its promise of more effective, safer, and equitable care. What remains clear is that the era of treating every patient identically is drawing to a close.